Worth reading
59In focus
Scored from 4 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
51.5
Year-on-year change in operating income (%)Wording
Conditional
How definitive the wording is.Results for this period
First quarter1 April 2026 to 30 June 2026ConsolidatedJapanese GAAPNet Sales826,157JPY millionYear on year +11.9%Progress 25.4%
Operating profit81,305JPY millionYear on year +51.5%Progress 32.8%
Ordinary income85,330JPY millionYear on year +70.8%Progress 34.5%
Net income attributable to owners of the parent53,766JPY millionYear on year +172.7%
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥39.73
Financial position at period-end
Total assets4,456,791JPY million
of which net assets 2,196,726 JPY millionEquity ratio 47.5%vs. prior year-end -3.0pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+14,254
Investment-195,535
Financials+185,969
Net change+4,688
Stacked from zero: upward is an increase in cash, downward a decrease (in JPY million).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period382,805 JPY million
Segment revenue
Healthcare190,78723.1%
Housing267,56032.4%
Materials360,15843.6%
Other7,6520.9%
Segment profit
Healthcare29,76033.4%
Housing20,17622.7%
Materials38,80943.6%
Other2960.3%
Outlook and shareholder returns
Full-year earnings forecast
Net Sales3,254,000 JPY million (YoY +5.8%)
Operating profit248,000 JPY million (YoY +7.3%)
Ordinary income247,500 JPY million (YoY +7.4%)
Profit attributable to owners of the parent160,000 JPY million (YoY +0.8%)
Revision to Earnings Forecast2Q cumulative Net Sales Not disclosed → 1,686,000 JPY million / Operating profit Not disclosed → 145,000 JPY million / Ordinary income Not disclosed → 149,000 JPY million / Profit attributable to owners of the parent Not disclosed → 89,000 JPY million / Full year Net Sales 3,254,000 JPY million → 3,254,000 JPY million / Operating profit 248,000 JPY million → 248,000 JPY million / Ordinary income 247,500 JPY million → 247,500 JPY million / Profit attributable to owners of the parent 160,000 JPY million → 160,000 JPY million
Annual Dividend Forecast42 JPY → 44 JPY
Factors Behind Changes in Business Performance
The factors behind changes in performance are described in the “Fiscal 2026 First-Quarter Financial Results Presentation” disclosed today on TDnet.
Disclosure regarding the going concern assumption
Not applicable.
Change in accounting policy
基準改正に伴う変更 Noそれ以外の変更 No見積りの変更 No修正再表示 No
Changes in the scope of consolidationNew Number of companies 6 / Company name Aicuris Anti-infective Cures AG and 5 of its subsidiaries / Excluded Not disclosed
Impairment loss54 JPY million
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of investment securities 2,320 JPY million, Gain on sale of non-current assets 350 JPY million / Extraordinary loss Losses on disposal of fixed assets 1,139 JPY million, Impairment Losses 54 JPY million, Business structure improvement expenses 350 JPY million
Depreciation and amortization43,129 JPY million
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingYes (for securities analysts and institutional investors)
Issued Shares at Period-End1,365,751,932
Treasury Shares at Period-End19,513,914
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 1 April 2026 to 30 June 2026 |
| Net Sales | 826,157 JPY million (YoY +11.9%) |
| Operating profit | 81,305 JPY million (YoY +51.5%) |
| Ordinary income | 85,330 JPY million (YoY +70.8%) |
| Profit attributable to owners of the parent | 53,766 JPY million (YoY +172.7%) |
| Net income per share | ¥39.73 |
| Equity ratio | End of the current fiscal period 47.5% / End of previous period 50.5% |
| Total assets | 4,456,791 JPY million |
| Net assets | 2,196,726 JPY million |
| Cash flows from operating activities | 14,254 JPY million |
| Cash flows from investing activities | -195,535 JPY million |
| Cash flows from financing activities | 185,969 JPY million |
| Cash and cash equivalents at end of period | 382,805 JPY million |
| Full-year earnings forecast | Net Sales 3,254,000 JPY million (YoY +5.8%) / Operating profit 248,000 JPY million (YoY +7.3%) / Ordinary income 247,500 JPY million (YoY +7.4%) / Profit attributable to owners of the parent 160,000 JPY million (YoY +0.8%) |
| Revision to Earnings Forecast | 2Q cumulative Net Sales Not disclosed → 1,686,000 JPY million / Operating profit Not disclosed → 145,000 JPY million / Ordinary income Not disclosed → 149,000 JPY million / Profit attributable to owners of the parent Not disclosed → 89,000 JPY million / Full year Net Sales 3,254,000 JPY million → 3,254,000 JPY million / Operating profit 248,000 JPY million → 248,000 JPY million / Ordinary income 247,500 JPY million → 247,500 JPY million / Profit attributable to owners of the parent 160,000 JPY million → 160,000 JPY million |
| Annual Dividend Forecast | 42 JPY → 44 JPY |
| Segment revenue | Healthcare 190,787 JPY million / Housing 267,560 JPY million / Materials 360,158 JPY million / Other 7,652 JPY million |
| Segment profit | Healthcare 29,760 JPY million / Housing 20,176 JPY million / Materials 38,809 JPY million / Other 296 JPY million |
| Depreciation and amortization | 43,129 JPY million |
| Impairment loss | 54 JPY million |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of investment securities 2,320 JPY million, Gain on sale of non-current assets 350 JPY million / Extraordinary loss Losses on disposal of fixed assets 1,139 JPY million, Impairment Losses 54 JPY million, Business structure improvement expenses 350 JPY million |
| Disclosure regarding the going concern assumption | Not applicable. |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Changes in the scope of consolidation | New Number of companies 6 / Company name Aicuris Anti-infective Cures AG and 5 of its subsidiaries / Excluded Not disclosed |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for securities analysts and institutional investors) |
| Issued Shares at Period-End | 1,365,751,932 |
| Treasury Shares at Period-End | 19,513,914 |
| Factors Behind Changes in Business Performance | The factors behind changes in performance are described in the “Fiscal 2026 First-Quarter Financial Results Presentation” disclosed today on TDnet. |
Items this document does not state (6)
Operating MarginPayout ratioShareholder Return PolicyRegional salesOrders received and order backlogMaterial subsequent events
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.This summary does not explain the factors behind changes in performance and refers to the “Fiscal 2026 First-Quarter Financial Results Presentation” disclosed on the same day.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.